Neurocrine Biosciences, Inc. Overview
Pro stress-test →Neurocrine Biosciences discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders, with flagship products including INGREZZA for tardive dyskinesia and CRENESSITY for congenital adrenal hyperplasia. The company is positioned as a specialty biopharmaceutical firm with a focus on movement disorders, reproductive health, and CNS conditions. INGREZZA demonstrated strong 12% year-over-year sales growth with record prescriptions, while CRENESSITY generated $98 million in Q3 net product sales.
Strategic Profile
Pro stress-test →Neurocrine leverages a broad, late-stage, and diversified CNS pipeline including multiple Phase III programs targeting major depressive disorder and schizophrenia, with precision medicine advances increasing visibility for future earnings. The company is expanding its sales force by approximately 30% to bolster INGREZZA adoption and broaden prescriber reach, with expectations for INGREZZA to reach ~$3 billion in sales by 2028 and CRENESSITY targeting peak revenues exceeding $1 billion by 2030.
Competitive Landscape
Pro stress-test →Neurocrine faces competition in movement disorders and neuropsychiatric conditions from larger biopharmaceutical companies developing similar CNS therapies. Primary competitive pressures center on INGREZZA in the tardive dyskinesia market, where market penetration efforts may face headwinds from alternative treatment options. The company's late-stage pipeline targeting depression and schizophrenia will compete with established players in psychiatric care.
Industry Context
Neurocrine Biosciences, Inc. operates in Specialty Biopharmaceuticals - CNS/Psychiatric/Endocrine Disorders.
Key facts
Founded: 1992 · Headquarters: San Diego, US · Employees: Unknown · Revenue: $2.86B (2026 forecast) · Market cap: $12.3B